Table 3 HDAC inhibitors in currently active clinical trials for breast cancer. All trial information was obtained from clinicaltrials.gov. PD1: programmed cell death protein 1; CTLA4: cytotoxic T-lymphocyte associated protein 4
Drug name | Phase | Conditions | In combination with | NCT number |
|---|---|---|---|---|
Vorinostat | 1 | Relapsed/refractory and/or metastatic breast cancer | PARP inhibitor olaparib | NCT03742245 |
1 | Operable HER2- breast cancer | Chemotherapy carboplatin Chemotherapy nab-paclitaxel | NCT00616967 | |
Belinostat | 1 | Metastatic TNBC | CDK4/6 inhibitor ribociclib | NCT04315233 |
1 | Metastatic breast cancer | PARP inhibitor talazoparib | NCT04703920 | |
Romidepsin | 1/2 | Metastatic TNBC BRCA mutation-associated recurrent/metastatic breast cancer | Chemotherapy cisplatin Anti-PD1 nivolumab | NCT02393794 |
Entinostat | 3 | Advanced/metastatic ER+/PR+/HER2- breast cancer | Endocrine therapy exemestane | NCT02115282 |
1 | Advanced/metastatic HER2- breast cancer | Anti-PD1 nivolumab and anti-CTLA4 ipilimumab | NCT02453620 | |
Chidamide (Tucidinostat) | 2 | Metastatic TNBC | Chemotherapy capecitabine | NCT05390476 |
Anti-PD1 zimberelimab | NCT05632848 | |||
1/2 | Advanced TNBC | Chemotherapy vincristine | NCT05747313 | |
2 | Advanced ER+/PR+/HER2- breast cancer | Chemotherapy nab-paclitaxel | NCT05633914 | |
PARP inhibitor fluzoparib | NCT05085626 | |||
2 | Early ER/PR-low, HER2- breast cancer | Anti-PD1 Chemotherapy paclitaxel | NCT05749575 | |
1/2 | Metastatic/relapsed ER+/PR+/HER2- breast cancer failed CDK4/6 inhibitor treatment | CDK4/6 inhibitor abemaciclib Endocrine therapy | NCT05464173 | |
1/2 | Chemotherapy eribulin | NCT05335473 | ||
2 | Endocrine therapy Chemotherapy capecitabine | NCT05411380 | ||
2 | Advanced ER+/PR+/HER2- breast cancer with PIK3CA mutation | mTOR inhibitor everolimus Endocrine therapy | NCT05983107 |